GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions

• Billy Bennett

Hepatocellular carcinoma is essentially the most frequent major liver most cancers. Macroautophagy/autophagy inhibitors have been extensively studied in most cancers however, thus far, none has reached efficacy in medical trials. On this research, we demonstrated that GNS561, a brand new autophagy inhibitor, whose anticancer exercise was beforehand linked to lysosomal cell loss of life, displayed…